CoChat

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment

Open access
McGill, Janet B., Sloan, Lance, Newman, Jennifer, Patel, Sanjay, Sauce, Christophe, von Eynatten, Maximilian, Woerle, Hans-Juergen · 2013 · Diabetes Care
Cited by 204

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This placebo-controlled study assessed long-term efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes and severe renal impairment (RI). RESEARCH DESIGN AND METHODS: In this 1-year, double-blind study, 133 patients with type 2 diabetes (HbA1c 7.0–10.0%) and severe RI (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2) at screening were randomized to linagliptin 5 mg (n = 68) or placebo (n = 65) once daily, added to existing background therapy. The primary efficacy end point was HbA1c change from baseline to week 12. Efficacy and safety end points were assessed after 1 year. RESULTS: At week 12, adjusted mean HbA1c decreased by −0.76% with linagliptin and −0.15% with placebo (treatment difference, −0.60%; 95% CI −0.89 to −0.31; P < 0.0001). HbA1c improvements were sustained with linagliptin (−0.71%) over placebo (0.01%) at 1 year (treatment difference −0.72%, −1.03 to −0.41; P < 0.0001). Mean insulin doses decreased by −6.2 units with linagliptin and −0.3 units with placebo. Overall adverse event incidence was similar over 1 year (94.1 vs. 92.3%). Incidence of severe hypoglycemia with linagliptin and placebo was comparably low (three patients per group). Linagliptin and placebo had little effect on renal function (median change in eGFR, −0.8 vs. −2.2 mL/min/1.73 m2), and no drug-related renal failure occurred. CONCLUSIONS: In patients with type 2 diabetes and severe RI, linagliptin provided clinically meaningful improvements in glycemic control with very low risk of severe hypoglycemia, stable body weight, and no cases of drug-related renal failure. The potential for linagliptin to spare insulin and provide long-term renal safety warrants further investigations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-0706

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. Whiting, 2011, IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030, Diabetes Res Clin Pract, 94, 311, 10.1016/j.diabres.2011.10.029 · DOI · Paper page
  2. Grassmann, 2005, ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends, Nephrol Dial Transplant, 20, 2587, 10.1093/ndt/gfi159 · DOI · Paper page
  3. Atkins, 2005, The epidemiology of chronic kidney disease, Kidney Int Suppl, 94, S14, 10.1111/j.1523-1755.2005.09403.x · DOI · Paper page
  4. Molitch, 2004, Nephropathy in diabetes, Diabetes Care, 27, S79, 10.2337/diacare.27.2007.S79 · DOI · Paper page
  5. Khuwaja, 2010, The economic costs of diabetes in developing countries: some concerns and recommendations, Diabetologia, 53, 389, 10.1007/s00125-009-1581-7 · DOI
  6. American Diabetes Association, 2011, Standards of medical care in diabetes—2011, Diabetes Care, 34, S11, 10.2337/dc11-S011 · DOI · Paper page
  7. Bakris, 2011, Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus, Mayo Clin Proc, 86, 444, 10.4065/mcp.2010.0713 · DOI
  8. Shrishrimal, 2009, Managing diabetes in hemodialysis patients: observations and recommendations, Cleve Clin J Med, 76, 649, 10.3949/ccjm.76a.09054 · DOI · Paper page
  9. Blech, 2010, The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans, Drug Metab Dispos, 38, 667, 10.1124/dmd.109.031476 · DOI · Paper page
  10. Heise, 2009, Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients, Diabetes Obes Metab, 11, 786, 10.1111/j.1463-1326.2009.01046.x · DOI · Paper page
  11. Deacon, 2011, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review, Diabetes Obes Metab, 13, 7, 10.1111/j.1463-1326.2010.01306.x · DOI · Paper page
  12. Deacon, 2010, Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes, Expert Opin Investig Drugs, 19, 133, 10.1517/13543780903463862 · DOI · Paper page
  13. Graefe-Mody, 2011, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin, Diabetes Obes Metab, 13, 939, 10.1111/j.1463-1326.2011.01458.x · DOI · Paper page
  14. Del Prato, 2011, Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, Diabetes Obes Metab, 13, 258, 10.1111/j.1463-1326.2010.01350.x · DOI · Paper page
  15. Forst, 2011, The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 13, 542, 10.1111/j.1463-1326.2011.01386.x · DOI
  16. Kawamori, 2012, Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study, Diabetes Obes Metab, 14, 348, 10.1111/j.1463-1326.2011.01545.x · DOI
  17. Taskinen, 2011, Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 13, 65, 10.1111/j.1463-1326.2010.01326.x · DOI · Paper page
  18. Owens, 2011, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study, Diabet Med, 28, 1352, 10.1111/j.1464-5491.2011.03387.x · DOI · Paper page
  19. Gomis, 2011, Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 13, 653, 10.1111/j.1463-1326.2011.01391.x · DOI · Paper page
  20. Schernthaner, 2012, Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus, Diabetes Obes Metab, 14, 470, 10.1111/j.1463-1326.2012.01565.x · DOI
  21. UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  22. Ohkubo, 1995, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Res Clin Pract, 28, 103, 10.1016/0168-8227(95)01064-K · DOI · Paper page
  23. Chapelsky, 2003, Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency, J Clin Pharmacol, 43, 252, 10.1177/0091270002250602 · DOI
  24. Kothny, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency, Diabetes Obes Metab.
  25. Nowicki, 2011, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment, Diabetes Obes Metab, 13, 523, 10.1111/j.1463-1326.2011.01382.x · DOI
  26. Nowicki, 2011, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study, Int J Clin Pract, 65, 1230, 10.1111/j.1742-1241.2011.02812.x · DOI
  27. Chan, 2008, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency, Diabetes Obes Metab, 10, 545, 10.1111/j.1463-1326.2008.00914.x · DOI · Paper page
  28. Meyers, 2011, Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment, Postgrad Med, 123, 133, 10.3810/pgm.2011.05.2291 · DOI
  29. Friedrich, Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes, Am J Ther.
  30. Ritz, 2011, Limitations and future treatment options in type 2 diabetes with renal impairment, Diabetes Care, 34, S330, 10.2337/dc11-s242 · DOI
  31. Drucker, 2011, Cardiovascular safety and diabetes drug development, Lancet, 377, 977, 10.1016/S0140-6736(10)62299-4 · DOI
  32. Verge, 2010, Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes, Curr Diabetes Rev, 6, 191, 10.2174/157339910791658853 · DOI
  33. Johansen, 2012, Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme, Cardiovasc Diabetol, 11, 3, 10.1186/1475-2840-11-3 · DOI · Paper page

Cited by

See all 204

Metadata

Authors
McGill, J. B., Sloan, L., Newman, J., Patel, S., Sauce, C., von Eynatten, M., & Woerle, H.-J.
Venue
Diabetes Care
Published
2013-01-17
Volume
36
Issue
2
Pages
237-244
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2100987099
Cited by
204
References
5
FWCI
20.71
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.